Statins may be beneficial for patients with slow coronary flow syndrome due to its anti-inflammatory property

Medical Hypotheses

Volumn 69, Issue 2, 2007, Pages 333-337

  Li, Jian Jun ^a   Zheng, Xin ^a   Li, Jie ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANGIOCARDIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DISEASE COURSE; EPICARDIUM; EXERCISE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; MATHEMATICAL MODEL; PATHOPHYSIOLOGY; PLEIOTROPY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SLOW CORONARY FLOW SYNDROME; SMALL VESSEL VASCULITIS; THORAX PAIN; THROMBOCYTE DYSFUNCTION; VASOCONSTRICTION; VASODILATATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SYNDROME;

ANGINA;

EID: 34249316220     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.09.070     Document Type: Article

References (33)

1. Goel P.K., Gupta S.K., Agarwal A., et al. Slow coronary flow: a distinct angiographic subgroup in syndrome X. Angiology 52 (2001) 507-514
2. Tambe A.A., Demany M.A., Zimmerman H.A., et al. Angina pectoris and slow flow velocity of dye in coronary arteries- a new angiographic finding. Am Heart J 84 (1972) 66-71
3. Li J.-J., et al. Should slow coronary flow be considered as a new coronary syndrome?. Med Hypotheses 66 (2006) 953-956
4. Burchartt B.A., Mukeriji V., Alpert M.A., et al. Coronary artery slow flow associated with angina pectoris and hypertension: a case report. Angiology 49 (1998) 483-487
5. Przybojewski J.Z., and Becker P.H. Angina pectoris and acute myocardial infarction due to "slow-flow phenomenon" in nonatherosclerotic coronary arteries: a case report. Angiology 37 (1986) 751-761
6. Mangieri E., Macchiarelli Ciavolella M., et al. Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn 37 (1996) 375-381
7. Stone G.W., Brodie B.R., Griffin J.J., et al. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial. Primary angioplasty in myocardial infarction stent pilot trial investigators. J Am Coll Cardiol 31 (1998) 23-30
8. Gibson C.M., Cannon C.P., Daley W.L., et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 93 (1996) 879-888
9. Li J.-J. Atheroscleritis is a more rational term for the pathological entity currently known as atherosclerosis. Med Hypotheses 63 (2004) 100-102
10. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
11. Shah P.K. Inflammation, neointimal hyperplasia, and restenosis: as the leukocytes roll, the arteries thicken. Circulation 107 (2003) 2175-2177
12. Li J.-J., et al. Is slow coronary flow associated with inflammation?. Med Hypotheses 66 (2006) 504-508
13. Li J.-J. Inflammation: an important mechanism for different clinical entities of coronary artery disease. Chin Med J 118 21 (2005) 1817-1826
14. Ko D.T., Mamdani M., and Alter D.A. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 291 (2004) 1864-1870
15. Sparrow C.P., Burton C.A., and Hernandez M. Simvastatin has anti-inflammatory and anti-atherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 21 (2001) 115-121
16. Li J.-J., Fang C.-H., Qian H.-Y., et al. Time course of rapid C-reactive protein reduction by pravastatin in patients with stable angina. Angiology 57 (2006) 1-7
17. Mosseri M., Yarom R., Gotsman M.S., et al. Histologic evidence for small vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation 74 (1986) 964-972
18. Kelly R.F., Sompalli V., Sattar P., et al. Increased TIMI frame counts in cocaine users: a case for increased microvascular resistance in the absence of epicardial coronary disease or spasm. Clin Cardiol 26 (2003) 319-322
19. Pedkdemir H., Cin V.G., Cicek D., et al. Slow coronary flow may be a sign of diffuse atherosclerosis: contribution of FFR and IVUS. Acta Cardiol 59 (2004) 127-133
20. Mintz G.S., Painter J.A., Pichard A.D., et al. Atherosclerosis in angiographically "normal" coronary artery reference segments: an intravascular ultrasound study with clinical correlations. J Am Coll Cardiol 25 (1995) 1479-1485
21. Rim S.J., Leong-Poi H., Lindner J.R., et al. Decrease in coronary blood flow reserve during hyperlipidemia is secondary to an increase in blood viscosity. Circulation 104 (2001) 2704-2709
22. Van Lierde J., Vrolix M., Sionis D., et al. Lack of evidence for small vessel disease in a patients with "slow dye progression" in the coronary arteries. Cathet Cardiovasc Diagn 23 (1991) 117-122
23. Pekdemir H., Polat G., Cin G., et al. Elevated plasma endothelin-1 levels in coronary sinus during rapid right atrial pacing in patients with slow coronary flow. Int J Cardiol 97 (2004) 35-41
24. Camsari A., Pekdemir H., Cicek D., et al. Endothelin-1 and nitric oxide concentrations and their response to exercise in patients with slow coronary flow. Circ J 67 (2003) 1022-1028
25. Sezgin N., Barutcu I., Sezgin A.T., et al. Plasma nitric oxide level and its role in slow coronary phenomenon. Int Heart J 46 (2005) 373-382
26. Lanza G.A., Andreotti F., Sestio A., et al. Platelet aggregability in cardiac syndrome X. Eur Heart J 22 (2001) 1924-1930
27. Gokce M., Kaplan S., Tekelioglu Y., et al. Platelet function disorder in patients with coronary slow flow. Clin Cardiol 28 (2005) 145-148
28. Turhan H., Saydam G.S., Erbay A.R., et al. Increased plasma soluble adhesion molecules: ICAM-1, VCAM-1, and E-selectin levels in patients with slow coronary flow. Int J Cardiol 98 (2005) 450-456
29. Li J-J, Qin X-W, Gao Z, et al. Elevated C-reactive protein and Interleukin-6 in patients with slow coronary flow. Clin Chim Acta 2007; in press.
30. Diomede L., Abain D., and Scttocorno M. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 21 (2001) 1327-1332
31. Kimura M., Kurose I., and Rusell J. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol 17 (1997) 1521-1526
32. Stalker T.J., Lefer A.M., and Scalla R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol 133 (2001) 406-412
33. Sparrow C.P., Burton C.A., and Hernandez M. Simvastatin has anti-inflammatory and anti-atherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 21 (2001) 115-121